Nettet28. jun. 2024 · Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the … Nettet30. nov. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based …
Intellia Therapeutics Announces Proposed Public Offering of …
Nettet2. jul. 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the closing of an underwritten public offering of … Nettet13. apr. 2024 · Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Rating) by 0.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,976,002 shares of the company's stock after acquiring an green flowered clematis
Intellia Therapeutics Announces Proposed Public Offering of …
Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of … Nettet1. des. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based … Nettet5. mai 2016 · CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public offering of 6,000,000 … green flowered hedgehog